2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on Laboratory Diagnostics of Lipid Metabolism Disorders

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2024 May 17

PMID 38757022

Authors

Bogdan Solnica

Grazyna Sygitowicz

Dariusz Sitkiewicz

Jacek Jozwiak

Slawomir Kasperczyk

Marlena Broncel

Anna Wolska

Grazyna Odrowaz-Sypniewska

Maciej Banach

Affiliations

Soon will be listed here.

Abstract

Lipid disorders are the most common (even 70%) and worst monitored cardiovascular risk factor (only 1/4 of patients in Poland and in CEE countries are on the low-density lipoprotein cholesterol (LDL-C) goal). To improve this, clear and simple diagnostic criteria should be introduced for all components of the lipid profile. These are the updated guidelines of the two main scientific societies in Poland in the area - the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA), which, in comparison to those from 2020, introduce few important changes in recommendations (two main lipid targets, new recommendations on LDL-C measurements, calculations new goals for triglycerides, new recommendations on remnants and small dense LDL) that should help the practitioners to be early with the diagnosis of lipid disorders and in the effective monitoring (after therapy initiation), and in the consequence to avoid the first and recurrent cardiovascular events.

Citing Articles

The prevention opportunities of retinopathy in diabetic patients - position paper endorsed by the Polish Lipid Association.

Banach M, Surma S, Dzida G, Jozwiak J, Okopien B, Rysz J Arch Med Sci. 2025; 20(6):1754-1769.

PMID: 39967951 PMC: 11831340. DOI: 10.5114/aoms/197331.

A Set of Proximal Regulatory Elements Contribute to the Transcriptional Activity of the Human Lipoprotein Lipase Promoter.

Bastaki N, Albarjes T, Mohamed A, Sabri N, Al-Bustan S Curr Issues Mol Biol. 2024; 46(11):13209-13222.

PMID: 39590382 PMC: 11592473. DOI: 10.3390/cimb46110788.

2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP).

Banach M, Reiner Z, Surma S, Bajraktari G, Bielecka-Dabrowa A, Bunc M Drugs. 2024; 84(12):1541-1577.

PMID: 39497020 PMC: 11652584. DOI: 10.1007/s40265-024-02105-5.

The Impact of Atorvastatin Treatment on the Distribution of Low-Density Lipoprotein Subfractions and the Level of Vitamin D in Patients After Acute Myocardial Infarction: Preliminary Findings.

Sygitowicz G, Sitkiewicz D, Wrzosek K, Dluzniewski M Int J Mol Sci. 2024; 25(20).

PMID: 39457047 PMC: 11508669. DOI: 10.3390/ijms252011264.

References

Dobrowolski P, Prejbisz A, Kurylowicz A, Baska A, Burchardt P, Chlebus K . Metabolic syndrome - a new definition and management guidelines: A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish.... Arch Med Sci. 2022; 18(5):1133-1156. PMC: 9479724. DOI: 10.5114/aoms/152921. View

Cao J, Steffen B, Guan W, Budoff M, Michos E, Kizer J . Evaluation of Lipoprotein(a) Electrophoretic and Immunoassay Methods in Discriminating Risk of Calcific Aortic Valve Disease and Incident Coronary Heart Disease: The Multi-Ethnic Study of Atherosclerosis. Clin Chem. 2017; 63(11):1705-1713. DOI: 10.1373/clinchem.2016.270751. View

Makover M, Surma S, Banach M, Toth P . Eliminating atherosclerotic cardiovascular disease residual risk. Eur Heart J. 2023; 44(45):4731-4733. DOI: 10.1093/eurheartj/ehad446. View

Camont L, Chapman M, Kontush A . Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med. 2011; 17(10):594-603. DOI: 10.1016/j.molmed.2011.05.013. View

Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Back M . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484. View

Sampson M, Wolska A, Warnick R, Lucero D, Remaley A . A New Equation Based on the Standard Lipid Panel for Calculating Small Dense Low-Density Lipoprotein-Cholesterol and Its Use as a Risk-Enhancer Test. Clin Chem. 2021; 67(7):987-997. PMC: 8260186. DOI: 10.1093/clinchem/hvab048. View

Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan R, Antunes M . 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39):4043-4140. DOI: 10.1093/eurheartj/ehad192. View

Banach M, Jankowski P, Jozwiak J, Cybulska B, Windak A, Guzik T . PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Arch Med Sci. 2017; 13(1):1-45. PMC: 5206369. DOI: 10.5114/aoms.2017.64712. View

Ganjali S, Mahdipour E, Aghaee-Bakhtiari S, Ghayour-Mobarhan M, Saffar Soflaei S, Banach M . Compositional and functional properties of high-density lipoproteins in relation to coronary in-stent restenosis. Arch Med Sci. 2023; 19(1):57-72. PMC: 9897092. DOI: 10.5114/aoms/140728. View

10.

Martin S, Jones S, Toth P . High-density lipoprotein subfractions: current views and clinical practice applications. Trends Endocrinol Metab. 2014; 25(7):329-36. DOI: 10.1016/j.tem.2014.05.005. View

11.

Ferretti G, Bacchetti T, Johnston T, Banach M, Pirro M, Sahebkar A . Lipoprotein(a): A missing culprit in the management of athero-thrombosis?. J Cell Physiol. 2017; 233(4):2966-2981. DOI: 10.1002/jcp.26050. View

12.

Bansal E, Kaur N . Does friedewald formula underestimate the risk of ischemic heart disease?. Indian J Clin Biochem. 2014; 29(4):496-500. PMC: 4175698. DOI: 10.1007/s12291-013-0392-2. View

13.

Kidawa M, Gluba-Brzozka A, Zielinska M, Franczyk B, Banach M, Rysz J . Cholesterol Subfraction Analysis in Patients with Acute Coronary Syndrome. Curr Vasc Pharmacol. 2018; 17(4):365-375. DOI: 10.2174/1570161116666180601083225. View

14.

Rosenson R, Brewer Jr H, Chapman M, Fazio S, Hussain M, Kontush A . HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011; 57(3):392-410. DOI: 10.1373/clinchem.2010.155333. View

15.

Maierean S, Mikhailidis D, Toth P, Grzesiak M, Mazidi M, Maciejewski M . The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review. Expert Opin Investig Drugs. 2018; 27(5):427-435. DOI: 10.1080/13543784.2018.1465927. View

16.

Davidson W . HDL-C vs HDL-P: how changing one letter could make a difference in understanding the role of high-density lipoprotein in disease. Clin Chem. 2014; 60(11):e1-3. DOI: 10.1373/clinchem.2014.232769. View

17.

Madsen C, Varbo A, Nordestgaard B . Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017; 38(32):2478-2486. DOI: 10.1093/eurheartj/ehx163. View

18.

Warnick G, Nauck M, Rifai N . Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem. 2001; 47(9):1579-96. View

19.

Ganjali S, Dallinga-Thie G, Simental-Mendia L, Banach M, Pirro M, Sahebkar A . HDL functionality in type 1 diabetes. Atherosclerosis. 2017; 267:99-109. DOI: 10.1016/j.atherosclerosis.2017.10.018. View

20.

Yang N, Wang M, Liu J, Liu J, Hao Y, Zhao D . The Level of Remnant Cholesterol and Implications for Lipid-Lowering Strategy in Hospitalized Patients with Acute Coronary Syndrome in China: Findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project. Metabolites. 2022; 12(10). PMC: 9607962. DOI: 10.3390/metabo12100898. View